<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648007</url>
  </required_header>
  <id_info>
    <org_study_id>TSOI-003</org_study_id>
    <nct_id>NCT04648007</nct_id>
  </id_info>
  <brief_title>Validation of Kaihani Score for Gambling Addiction</brief_title>
  <official_title>Diagnostic Ability of Plasma Based Neuromodulatory Cytokine Production (Kaihani Score) in Gambling Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutic Solutions International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapeutic Solutions International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Kaihani Score is a blood based means of assessing molecules believed to be associated&#xD;
      with gambling addiction.&#xD;
&#xD;
      The current clinical trial will assess the Kaihani Score in 3 groups:&#xD;
&#xD;
      Group 1: 10 patients with no personal or family problems with gambling as assessed by the&#xD;
      PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological&#xD;
      gambling) (PG-YBOCS).&#xD;
&#xD;
      Group 2: 10 patients with moderate gambling addiction as assessed by the PG-YBOCS&#xD;
      (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling)&#xD;
      (PG-YBOCS).&#xD;
&#xD;
      Group 3: 10 patients with severe gambling addiction as assessed by the PG-YBOCS&#xD;
      (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling)&#xD;
      (PG-YBOCS).&#xD;
&#xD;
      The goal of the study is to confirm preliminary efficacy of the Kaihani Score as a blood&#xD;
      based means of assessing gambling propensity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Kaihani Score</measure>
    <time_frame>1 Week</time_frame>
    <description>Kaihani Score will be compared between non-gamblers, moderate gamblers, and severe gamblers.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gambling Addiction</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>10 patients with no personal or family problems with gambling as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Gamblers</arm_group_label>
    <description>10 patients with moderate gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Gamblers</arm_group_label>
    <description>10 patients with severe gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Kaihani Score</intervention_name>
    <description>Assessment of neuromodulatory chemicals in peripheral blood plasma samples.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Moderate Gamblers</arm_group_label>
    <arm_group_label>Severe Gamblers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will comprise of 10 healthy volunteers, as well as 20 patients with&#xD;
        gambling addictions. 10 of the patients will have moderate and 10 will have severe gambling&#xD;
        addiction.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of pathological gambling (DSM IV criteria)&#xD;
&#xD;
          -  First-time consultants.&#xD;
&#xD;
          -  Without psychotropic treatment or treatment with a stable and unchanged for over a&#xD;
             month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women and patients with hearing disorders&#xD;
&#xD;
          -  Epilepsy (untreated or poorly balanced)&#xD;
&#xD;
          -  Focal brain injury, whatever its origin (vascular, traumatic, tumor or infectious)&#xD;
&#xD;
          -  History of head trauma with loss of consciousness,&#xD;
&#xD;
          -  Administration of drugs or substances lowering the seizure threshold&#xD;
&#xD;
          -  Sleep deprivation, jet lag, or drug withdrawal.&#xD;
&#xD;
          -  Participants with a problem of uncorrected visual acuity.&#xD;
&#xD;
          -  Other current addiction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>James Veltmeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Therapeutic Solutions International</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wais Kaihani</last_name>
    <phone>619 909 2454</phone>
    <email>waiskaihani@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Ichim, PhD</last_name>
    <phone>858 353 4303</phone>
    <email>thomas.ichim@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Therapeutic Solutions International</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wais Kaihani</last_name>
      <phone>619-909-2454</phone>
      <email>waiskaihani@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Ichim</last_name>
      <phone>8583534303</phone>
      <email>thomas.ichim@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Veltmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>addiction</keyword>
  <keyword>BDNF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Gambling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

